SG11201607339VA - Methods and compositions for modulating estrogen receptor mutants - Google Patents
Methods and compositions for modulating estrogen receptor mutantsInfo
- Publication number
- SG11201607339VA SG11201607339VA SG11201607339VA SG11201607339VA SG11201607339VA SG 11201607339V A SG11201607339V A SG 11201607339VA SG 11201607339V A SG11201607339V A SG 11201607339VA SG 11201607339V A SG11201607339V A SG 11201607339VA SG 11201607339V A SG11201607339V A SG 11201607339VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- estrogen receptor
- receptor mutants
- modulating estrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952728P | 2014-03-13 | 2014-03-13 | |
| US201461981708P | 2014-04-18 | 2014-04-18 | |
| PCT/EP2015/055120 WO2015136017A1 (fr) | 2014-03-13 | 2015-03-12 | Méthodes et compositions pour moduler des mutants du récepteur des oestrogènes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201607339VA true SG11201607339VA (en) | 2016-10-28 |
Family
ID=52682706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607339VA SG11201607339VA (en) | 2014-03-13 | 2015-03-12 | Methods and compositions for modulating estrogen receptor mutants |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9855270B2 (fr) |
| EP (1) | EP3116496A1 (fr) |
| JP (1) | JP2017509631A (fr) |
| KR (1) | KR20160132029A (fr) |
| CN (1) | CN106488767A (fr) |
| AU (1) | AU2015228860A1 (fr) |
| BR (1) | BR112016020953A2 (fr) |
| CA (1) | CA2941161A1 (fr) |
| IL (1) | IL247250A0 (fr) |
| MA (1) | MA39740A (fr) |
| MX (1) | MX2016011698A (fr) |
| RU (1) | RU2016137150A (fr) |
| SG (1) | SG11201607339VA (fr) |
| WO (1) | WO2015136017A1 (fr) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9956276B2 (en) | 2012-01-19 | 2018-05-01 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| MX2015011132A (es) | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Moduladores policiclicos del receptor de estrogenos y sus usos. |
| MX2015017655A (es) | 2013-06-19 | 2016-04-15 | Seragon Pharmaceuticals Inc | Modulador de receptores de estrogeno y uso del mismo. |
| CA2915534A1 (fr) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Modulateurs azetidine des recepteurs d'oestrogenes et leurs utilisations |
| US10174381B2 (en) * | 2013-10-18 | 2019-01-08 | The Regents Of The University Of Michigan | Systems and methods for determining a treatment course of action |
| WO2016007499A1 (fr) | 2014-07-07 | 2016-01-14 | Duke University | Vaccins contre un isoforme oncogène d'her2 (erbb2) et leurs méthodes d'utilisation |
| CA2954279C (fr) | 2014-07-07 | 2023-11-14 | Duke University | Vaccins diriges contre une isoforme oncogene d'esr1 et leurs methodes d'utilisation |
| AR101487A1 (es) | 2014-08-11 | 2016-12-21 | Hoffmann La Roche | Formas cristalinas de un modulador de receptor de estrógeno |
| US9980947B2 (en) | 2014-12-18 | 2018-05-29 | Genentech, Inc. | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof |
| JP6807841B2 (ja) | 2014-12-18 | 2021-01-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーター及びその使用 |
| EP3274476B1 (fr) | 2015-03-25 | 2023-06-07 | The General Hospital Corporation | Analyse numérique de cellules tumorales circulantes dans des échantillons de sang |
| US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
| US9975856B2 (en) | 2015-10-07 | 2018-05-22 | Genentech, Inc. | Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid |
| CN108699024B (zh) | 2015-12-09 | 2022-03-11 | 伊利诺伊大学评议会 | 苯并噻吩基选择性雌激素受体下调剂化合物 |
| CN108697779B (zh) * | 2016-01-07 | 2023-09-19 | 杜克大学 | 癌症疫苗和递送方法 |
| BR112018015419B1 (pt) | 2016-02-05 | 2024-01-30 | Inventisbio Llc | Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica |
| SG10202007520WA (en) | 2016-03-02 | 2020-09-29 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| CA3018801C (fr) * | 2016-03-25 | 2020-06-23 | Luoxin Biotechnology (Shanghai) Co., Ltd | Composes a substitution indole comme agent de degradation des recepteursdes oestrogenes |
| JP7131773B2 (ja) | 2016-04-29 | 2022-09-06 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ホルモン受容体に関連する転写活性の標的尺度 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| US10695450B2 (en) | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
| EP3500681B1 (fr) * | 2016-08-18 | 2021-01-20 | Roche Diagnostics GmbH | Dosages pcr multiplex spécifiques à des allèles pour la détection de mutations du récepteur d'oestrogènes esr1 |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| BR112019007254A2 (pt) * | 2016-10-11 | 2019-07-02 | Univ Duke | tratamento lasofoxifeno de câncer de mama er+ |
| WO2018081168A2 (fr) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Répresseurs du récepteur oestrogénique sélectifs mixtes à base de benzothiophène |
| EP3985127A1 (fr) * | 2016-10-27 | 2022-04-20 | The General Hospital Corporation | Analyse numérique d'échantillons de sang pour déterminer l'efficacité de thérapies anticancéreuses pour des cancers spécifiques |
| KR102576011B1 (ko) | 2017-01-06 | 2023-09-06 | 쥐원 쎄라퓨틱스, 인크. | 암의 치료를 위한 조합 요법 |
| WO2018148576A1 (fr) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Modulateurs du récepteur des œstrogènes de benzothiophène |
| US20210094899A1 (en) * | 2017-07-28 | 2021-04-01 | Recurium Ip Holdings, Llc | Acrylic acid analogs |
| WO2019057201A1 (fr) * | 2017-09-25 | 2019-03-28 | 罗欣生物科技（上海）有限公司 | Forme cristalline d'un inhibiteur du récepteur des œstrogènes et son procédé de préparation |
| BR112020008888A2 (pt) | 2017-11-16 | 2020-10-20 | Novartis Ag | terapias de combinação |
| TW201929902A (zh) * | 2017-12-27 | 2019-08-01 | 美商提薩羅有限公司 | 治療癌症之方法 |
| CN112261937B (zh) | 2018-04-10 | 2023-11-14 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| UA128114C2 (uk) | 2018-06-21 | 2024-04-10 | Ф. Хоффманн-Ля Рош Аг | Тверді форми 3-((1r,3r)-1-(2,6-дифтор-4-((1-(3-фторпропіл)азетидин-3-іл)аміно)феніл)-3-метил-1,3,4,9-тетрагідро-2h-піридo[3,4-b]індол-2-іл)-2,2-дифторпропан-1-олу і способи одержання конденсованих трициклічних сполук, що містять заміщене фенільне або піридинільне угруповання, в тому числі способи їх застосування |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN111184863B (zh) * | 2018-11-15 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 |
| JP7416540B2 (ja) * | 2018-11-28 | 2024-01-17 | 羅欣薬業（上海）有限公司 | エストロゲン受容体ダウンレギュレーターの塩形態、結晶形及びその製造方法 |
| WO2020128972A1 (fr) | 2018-12-20 | 2020-06-25 | Novartis Ag | Schéma posologique et combinaison pharmaceutique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione |
| MX2021007687A (es) | 2018-12-24 | 2021-10-13 | Inventisbio Co Ltd | Sales novedosas de degradadores selectivos de receptores de estrogeno. |
| US20220144807A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN113329792A (zh) | 2019-02-15 | 2021-08-31 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| CA3136088A1 (fr) | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Conjugues anticorps-medicament inhibiteurs de mcl-1 et methodes d'utilisation |
| CN110982807B (zh) * | 2019-12-17 | 2022-04-29 | 云南农业大学 | 一种高效稳定的纤维素酶突变体 |
| US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| KR20220151616A (ko) * | 2020-03-06 | 2022-11-15 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체-연관 질환의 치료 방법 |
| EP4151636A4 (fr) * | 2020-05-15 | 2024-02-28 | Simcere pharmaceutical co ltd | Composé pyrrolidine et son utilisation |
| WO2021260528A1 (fr) | 2020-06-23 | 2021-12-30 | Novartis Ag | Schéma posologique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione |
| EP4188549A1 (fr) | 2020-08-03 | 2023-06-07 | Novartis AG | Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione substitués par hétéroaryle et leurs utilisations |
| AU2021388021A1 (en) | 2020-11-24 | 2023-06-22 | Novartis Ag | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
| CA3202759A1 (fr) | 2020-11-24 | 2022-06-02 | Novartis Ag | Conjugues anticorps-medicament inhibiteurs de mcl-1 et procedes d'utilisation |
| EP4288434A1 (fr) | 2021-02-02 | 2023-12-13 | Les Laboratoires Servier | Composés bcl-xl protac sélectifs et procédés d'utilisation |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2022245124A1 (fr) * | 2021-05-18 | 2022-11-24 | 재단법인 대구경북첨단의료산업진흥재단 | Nouveau composé d'éthène et composition pharmaceutique le comprenant en tant que principe actif pour la prévention ou le traitement du cancer |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN113293213A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测乳腺癌复发转移基因her2扩增的引物探针及其应用 |
| WO2023225336A1 (fr) | 2022-05-20 | 2023-11-23 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de met bcl-xl et leurs procédés d'utilisation |
| WO2023225320A1 (fr) | 2022-05-20 | 2023-11-23 | Novartis Ag | Conjugués anticorps-médicament inhibiteurs de bcl-xl et méthodes d'utilisation associées |
| WO2024033513A1 (fr) | 2022-08-11 | 2024-02-15 | Diaccurate | Composés pour le traitement du cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060503A (en) * | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| DE60035522T2 (de) * | 1999-12-07 | 2008-03-20 | Sumitomo Chemical Co., Ltd. | Mutant er-alpha und nachweissysteme für transaktivierung |
| ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2013056178A2 (fr) * | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Nouvelles mutations de récepteur des estrogènes et leurs utilisations |
| CA2857057A1 (fr) | 2011-12-14 | 2013-06-20 | Seragon Pharmaceuticals, Inc. | Modulateurs fluores des recepteurs d'strogenes et leurs utilisations |
| CA2857061A1 (fr) * | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Nouveaux composes benzopyranes, compositions et utilisations de ceux-ci |
| NZ630124A (en) | 2012-03-20 | 2016-01-29 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| MX2015011132A (es) * | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Moduladores policiclicos del receptor de estrogenos y sus usos. |
| WO2014196863A1 (fr) * | 2013-06-07 | 2014-12-11 | Keygene N.V. | Méthode de séquençage ciblé |
| KR20160027968A (ko) * | 2013-06-07 | 2016-03-10 | 라나 테라퓨틱스, 인크. | Ｆｏｘｐ3 발현을 조절하기 위한 조성물 및 방법 |
| MX2015017655A (es) | 2013-06-19 | 2016-04-15 | Seragon Pharmaceuticals Inc | Modulador de receptores de estrogeno y uso del mismo. |
| CA2915534A1 (fr) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Modulateurs azetidine des recepteurs d'oestrogenes et leurs utilisations |
| JP2016540767A (ja) | 2013-12-06 | 2016-12-28 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 局所進行性又は転移性エストロゲン受容体陽性乳がんの治療のためのエストロゲン受容体調節因子 |
| EP3116497A2 (fr) | 2014-03-13 | 2017-01-18 | F. Hoffmann-La Roche AG | Combinaisons thérapeutiques avec des modulateurs de récepteurs d' oestrogènes |
-
2015
- 2015-03-12 AU AU2015228860A patent/AU2015228860A1/en not_active Abandoned
- 2015-03-12 EP EP15709908.6A patent/EP3116496A1/fr not_active Withdrawn
- 2015-03-12 BR BR112016020953A patent/BR112016020953A2/pt not_active Application Discontinuation
- 2015-03-12 JP JP2016557076A patent/JP2017509631A/ja active Pending
- 2015-03-12 MA MA039740A patent/MA39740A/fr unknown
- 2015-03-12 SG SG11201607339VA patent/SG11201607339VA/en unknown
- 2015-03-12 US US14/645,578 patent/US9855270B2/en not_active Expired - Fee Related
- 2015-03-12 CA CA2941161A patent/CA2941161A1/fr not_active Abandoned
- 2015-03-12 MX MX2016011698A patent/MX2016011698A/es unknown
- 2015-03-12 RU RU2016137150A patent/RU2016137150A/ru not_active Application Discontinuation
- 2015-03-12 WO PCT/EP2015/055120 patent/WO2015136017A1/fr active Application Filing
- 2015-03-12 KR KR1020167025197A patent/KR20160132029A/ko unknown
- 2015-03-12 CN CN201580025224.0A patent/CN106488767A/zh active Pending
-
2016
- 2016-08-11 IL IL247250A patent/IL247250A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017509631A (ja) | 2017-04-06 |
| US20150258099A1 (en) | 2015-09-17 |
| KR20160132029A (ko) | 2016-11-16 |
| WO2015136017A1 (fr) | 2015-09-17 |
| BR112016020953A2 (pt) | 2018-01-23 |
| RU2016137150A3 (fr) | 2018-10-19 |
| IL247250A0 (en) | 2016-09-29 |
| CA2941161A1 (fr) | 2015-09-17 |
| AU2015228860A1 (en) | 2016-09-08 |
| MX2016011698A (es) | 2016-12-12 |
| RU2016137150A (ru) | 2018-04-18 |
| CN106488767A (zh) | 2017-03-08 |
| MA39740A (fr) | 2017-01-18 |
| US9855270B2 (en) | 2018-01-02 |
| EP3116496A1 (fr) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL247250A0 (en) | Methods and compositions for modulating estrogen receptor mutants | |
| HK1247199A1 (zh) | 雌激素受體調節劑及其用途 | |
| IL273058A (en) | Compositions and methods for modulation of PKK expression | |
| HK1257295A1 (zh) | 用於免疫腫瘤學的組合物和方法 | |
| IL272653A (en) | Preparations and methods for the modulation of growth hormone receptor expression | |
| HK1243333A1 (zh) | 用於修飾的t細胞的方法和組合物 | |
| IL249373A0 (en) | Polypeptide formulations of related detector and method | |
| IL271659A (en) | Compositions and methods for modulating expression of complement factor B | |
| EP3183349A4 (fr) | Procédés de préparation de rébaudioside i et utilisations associées | |
| IL246879B (en) | Preparations of Epilimod and methods of using them | |
| EP3212315A4 (fr) | Compositions et méthodes de formation d'émulsions | |
| GB201507781D0 (en) | Blending techniques for curve fitting | |
| IL268684A (en) | Preparations and methods for immuno-oncology | |
| GB201417828D0 (en) | New methods and compositions | |
| EP3094323A4 (fr) | Méthodes et compositions pour moduler les taux d'hormone | |
| IL274524A (en) | Preparations and methods for aquaculture | |
| EP3137624A4 (fr) | Compositions et procédés pour la modulation de mtorc1 | |
| IL249203B (en) | Androgen receptor modulators and methods of using them | |
| SG11201702475VA (en) | Methods and compositions for modulating th-gm cell function | |
| EP3227249A4 (fr) | Compositions et procédés permettant l'introduction de micronutriments | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
| EP3224230A4 (fr) | Modulateurs du récepteur des strogènes | |
| GB201405403D0 (en) | Receptor modulation |